IRIS
PINATO, David James
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.046
AS - Asia 6.454
EU - Europa 6.391
SA - Sud America 816
Continente sconosciuto - Info sul continente non disponibili 376
AF - Africa 340
OC - Oceania 6
Totale 21.429
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.744
SG - Singapore 2.506
RU - Federazione Russa 2.467
IE - Irlanda 1.239
CN - Cina 1.184
HK - Hong Kong 1.148
BR - Brasile 600
IT - Italia 590
VN - Vietnam 573
DE - Germania 430
FR - Francia 417
SE - Svezia 371
BD - Bangladesh 262
UA - Ucraina 217
BJ - Benin 206
GB - Regno Unito 186
IN - India 174
KR - Corea 157
CA - Canada 147
FI - Finlandia 98
AT - Austria 96
MX - Messico 91
AR - Argentina 73
JP - Giappone 73
PL - Polonia 58
ES - Italia 57
ID - Indonesia 53
ZA - Sudafrica 52
NL - Olanda 46
IQ - Iraq 44
TR - Turchia 44
CO - Colombia 36
IR - Iran 33
EC - Ecuador 29
LT - Lituania 29
PH - Filippine 27
MA - Marocco 26
PK - Pakistan 26
VE - Venezuela 22
SA - Arabia Saudita 19
CL - Cile 18
CZ - Repubblica Ceca 18
PY - Paraguay 15
UZ - Uzbekistan 15
BE - Belgio 14
CH - Svizzera 14
AE - Emirati Arabi Uniti 13
JM - Giamaica 13
OM - Oman 11
EG - Egitto 9
JO - Giordania 9
MY - Malesia 9
TN - Tunisia 9
CR - Costa Rica 8
KE - Kenya 8
NP - Nepal 8
PE - Perù 8
ET - Etiopia 7
IL - Israele 7
RS - Serbia 7
TT - Trinidad e Tobago 7
UY - Uruguay 7
BO - Bolivia 6
DO - Repubblica Dominicana 6
DZ - Algeria 6
GT - Guatemala 6
KZ - Kazakistan 6
PT - Portogallo 6
TH - Thailandia 6
TW - Taiwan 6
BG - Bulgaria 5
HN - Honduras 5
LB - Libano 5
PS - Palestinian Territory 5
SN - Senegal 5
AU - Australia 4
AZ - Azerbaigian 4
BH - Bahrain 4
SK - Slovacchia (Repubblica Slovacca) 4
AM - Armenia 3
BS - Bahamas 3
CY - Cipro 3
EU - Europa 3
HU - Ungheria 3
KG - Kirghizistan 3
LV - Lettonia 3
MN - Mongolia 3
NI - Nicaragua 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BF - Burkina Faso 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
BZ - Belize 2
CI - Costa d'Avorio 2
CW - ???statistics.table.value.countryCode.CW??? 2
KH - Cambogia 2
LC - Santa Lucia 2
Totale 21.026
Salva come PNG Salva come JPEG
Città #
Dublin 1.236
San Jose 1.155
Hong Kong 1.137
Singapore 961
Council Bluffs 678
Ashburn 636
Beijing 307
Moscow 296
Los Angeles 267
Lauterbourg 246
Cotonou 206
Santa Clara 202
Columbus 192
Ho Chi Minh City 160
Buffalo 149
Lawrence 149
Princeton 149
Jacksonville 146
New York 142
Wilmington 140
Hanoi 139
Seoul 137
San Mateo 125
Chandler 114
Dallas 91
Falkenstein 76
São Paulo 74
Novara 67
Nuremberg 67
Orem 63
Helsinki 58
Tokyo 58
Brooklyn 56
Chennai 55
Chicago 55
Dearborn 55
Frankfurt am Main 55
Mexico City 52
Vienna 51
Redondo Beach 48
Milan 46
Piemonte 46
St Louis 45
Toronto 44
Warsaw 43
Denver 42
Phoenix 42
Tianjin 42
Munich 41
London 40
Ann Arbor 38
Montreal 37
Assago 36
Stockholm 35
Haiphong 34
Houston 34
Johannesburg 34
Hangzhou 33
Atlanta 32
Boston 32
Guangzhou 32
Boardman 30
Da Nang 30
Turin 29
Amsterdam 27
Poplar 27
Manchester 25
Rome 25
Vercelli 25
San Francisco 24
Shanghai 24
Andover 23
Jakarta 22
Mumbai 22
Strasbourg 22
Shenzhen 20
Ankara 18
Bremen 18
Norwalk 17
Zanjan 16
Dhaka 15
Brasília 14
Roubaix 14
Brussels 13
Genoa 13
Las Vegas 13
Quito 13
Seattle 13
Tashkent 13
Baghdad 12
Pleasantville 12
The Dalles 12
Turku 12
Belo Horizonte 11
Istanbul 11
Manila 11
New Delhi 11
Rio de Janeiro 11
Woodbridge 11
Bologna 10
Totale 11.547
Salva come PNG Salva come JPEG
Nome #
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease 191
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 180
On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study 160
Long-term sequelae are highly prevalent one year after hospitalization for severe COVID-19 159
Determinants of long COVID among adults hospitalized for SARS-CoV-2 infection: A prospective cohort study 151
Time-Dependent COVID-19 Mortality in Patients with Cancer: An Updated Analysis of the OnCovid Registry 146
Validation of the Hepatoma Arterial Embolization Prognostic Score in European and Asian Populations and Proposed Modification. 143
Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma 143
L’impatto del Long COVID è stato minore nella terza ondata della pandemia rispetto alla prima ondata in una popolazione italiana di 324 pazienti. 142
Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinoma 137
Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib 137
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: The OnCovid Inflammatory Score 133
Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: A multi-center comparative study 132
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 132
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 130
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 129
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study 127
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer 127
Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe 127
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry 127
Prevalence and impact of COVID-19 sequelae on treatment pathways and survival of patients with cancer who recovered from SARS-Cov-2 infection: results from the OnCovid registry. 125
Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients 123
The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma 119
Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death 118
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 116
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries 113
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma 113
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study 113
Immunotherapy vs Best Supportive Care for Patients with Hepatocellular Cancer with Child-Pugh B Dysfunction 111
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 110
Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis. 110
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 110
Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study 109
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study 108
HBV AND LYMPHOMAGENESIS: NOVEL INSIGHTS INTO AN OCCULT RELATIONSHIP 107
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study 107
Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis 107
Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter? 104
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer 104
Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma 104
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC 103
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis 102
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma 100
Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study 100
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer 99
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer 99
Hepatitis B virus and lymphomagenesis: novel insights into an occult relationship 99
The albumin–bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development 99
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 98
Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study 98
ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma 98
Immunotherapies for hepatocellular carcinoma 97
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 97
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 96
T-cell mediated responses against alpha-foetoprotein in hepatocellular carcinoma: Relationship with hepatitis C virus infection, tumour phenotype and patients’ survival 96
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 95
Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry 95
Advanced age influences the dynamic changes in circulating C-reactive protein following injury 95
Antibiotic therapy and outcome from immune-checkpoint inhibitors 94
Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials 91
Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis 91
A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC 90
Merits and boundaries of the BCLC staging and treatment algorithm: Learning from the past to improve the future with a novel proposal 90
A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers 90
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 90
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 90
Acceleration of interstitial lung disease induced by raltitrexed 89
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors 87
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 87
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade 87
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma 86
A novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI) 86
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 85
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors 85
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study 85
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma 84
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma 84
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice 84
Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey 84
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions 84
Disturbances in sodium and chloride homeostasis predict outcome in stable and critically ill patients with cirrhosis 83
Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram 83
Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular Carcinoma 83
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma 82
Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapy-based systemic therapy 82
Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients 82
An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials 82
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma 82
Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma 81
Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213) 81
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 81
Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post-hoc analysis of the phase I/III IMpower 133 trial 81
Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents for the Treatment of Liver Malignancy 81
A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: The prognostic nutritional index (PNI) 81
The price and value of therapeutic synergy in liver cancer 80
Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A matching-adjusted indirect comparison 80
Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis 80
An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: Correlation with tumour phenotype and survival outcomes 79
Assessing the impact of COVID-19 on liver cancer management (CERO-19) 79
Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy 79
Totale 10.395
Salva come PNG Salva come JPEG
Categoria #
all - tutte 117.883
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 117.883
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022772 0 2 174 71 46 6 24 21 68 63 126 171
2022/20231.810 217 43 77 6 51 106 43 79 1.132 5 27 24
2023/20241.084 136 46 82 33 209 14 222 15 4 39 56 228
2024/20253.885 45 26 204 19 36 331 391 346 904 590 261 732
2025/202611.855 548 499 678 1.060 1.303 833 1.964 1.777 881 927 857 528
2026/20271.166 455 711 0 0 0 0 0 0 0 0 0 0
Totale 21.429